Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339812 | 0.80 | MAPT (0.71) | MAPTMAPK1TDP1L3MBTL1ALPG | |
| SCHEMBL15013285 | 0.79 | MAPT (0.55) | MAPTMAPK1TDP1L3MBTL1MEN1 | |
| SCHEMBL2305236 | 0.79 | NPC1 (0.68) | TDP1L3MBTL1MEN1KMT2AHTR1A | |
| SCHEMBL30015078 | 0.79 | NPC1 (0.68) | TDP1L3MBTL1MEN1KMT2AHTR1A | |
| Formaldehyde SCHEMBL27831678 | 0.78 | MAPT (0.63) | MAPTMAPK1TDP1L3MBTL1ALPG | |
| SCHEMBL13230076 | 0.77 | NPC1 (0.75) | MAPTMAPK1TDP1L3MBTL1MEN1 | |
| SCHEMBL9687632 | 0.76 | MAPT (0.67) | MAPTMEN1KMT2AHTR1AADRA1D | |
| SCHEMBL30318898 | 0.76 | HPD (0.49) | MAPTMAPK1TDP1L3MBTL1MEN1 | |
| SCHEMBL1121791 | 0.76 | HPD (0.49) | MAPTMAPK1TDP1L3MBTL1MEN1 | |
| SCHEMBL30823663 | 0.75 | ALDH1A1 (0.49) | MAPTMAPK1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670485-A4 | TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT | RESVERLOGIX CORP (CA) | 2009-03-11 | — | — | EP | disclosed |
| US-20070099826-A1 | Treatment of diseases associated with the egr-1 enhancer element | RESVERLOGIX CORP. (CA) | 2007-05-03 | — | — | US | disclosed |
| CN-1893957-A | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | RESVERLOGIX CORP (CA) | 2007-01-10 | — | — | CN | disclosed |
| EP-1670484-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2006-06-21 | — | — | EP | disclosed |
| EP-1670485-A1 | TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT | RESVERLOGIX CORP. (CA) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005034960-A1 | TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT | RESVERLOGIX CORP. (CA) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| WO-2005032559-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | NOS2, NOS3, NOS1 | MAPT 3600/4885MAPK1 1605/4885TDP1 718/4885 |
| US-20070099826-A1 | Treatment of diseases associated with the egr-1 enhancer element | TOE1, ATF1, ELF3 | MAPT 4779/4885MAPK1 272/4885TDP1 314/4885 |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | NOS2, NOS1, NOS3 | MAPT 2805/4885MAPK1 1296/4885TDP1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.